28420030|t|Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline
28420030|a|1 ESGE / EASL recommend that, as the primary diagnostic modality for PSC, magnetic resonance cholangiography (MRC) should be preferred over endoscopic retrograde cholangiopancreatography (ERCP). Moderate quality evidence, strong recommendation. 2 ESGE / EASL suggest that ERCP can be considered if MRC plus liver biopsy is equivocal or contraindicated in patients with persisting clinical suspicion of PSC. The risks of ERCP have to be weighed against the potential benefit with regard to surveillance and treatment recommendations. Low quality evidence, weak recommendation. 6 ESGE / EASL suggest that, in patients with an established diagnosis of PSC, MRC should be considered before therapeutic ERCP. Weak recommendation, low quality evidence. 7 ESGE / EASL suggest performing endoscopic treatment with concomitant ductal sampling (brush cytology, endobiliary biopsies) of suspected significant strictures identified at MRC in PSC patients who present with symptoms likely to improve following endoscopic treatment. Strong recommendation, low quality evidence. 9 ESGE / EASL recommend weighing the anticipated benefits of biliary papillotomy / sphincterotomy against its risks on a case-by-case basis. Strong recommendation, moderate quality evidence. Biliary papillotomy / sphincterotomy should be considered especially after difficult cannulation. Strong recommendation, low quality evidence. 16 ESGE / EASL suggest routine administration of prophylactic antibiotics before ERCP in patients with PSC. Strong recommendation, low quality evidence. 17 EASL / ESGE recommend that cholangiocarcinoma (CCA) should be suspected in any patient with worsening cholestasis, weight loss, raised serum CA19-9, and/or new or progressive dominant stricture, particularly with an associated enhancing mass lesion. Strong recommendation, moderate quality evidence. 19 ESGE / EASL recommend ductal sampling (brush cytology, endobiliary biopsies) as part of the initial investigation for the diagnosis and staging of suspected CCA in patients with PSC. Strong recommendation, high quality evidence.
28420030	8	17	endoscopy	T060	C0014245
28420030	21	51	primary sclerosing cholangitis	T047	C0566602
28420030	53	99	European Society of Gastrointestinal Endoscopy	T093	C1708333
28420030	101	105	ESGE	T093	C1708333
28420030	111	158	European Association for the Study of the Liver	T093	C1708333
28420030	160	164	EASL	T093	C1708333
28420030	166	184	Clinical Guideline	T170	C0282451
28420030	187	191	ESGE	T093	C1708333
28420030	194	198	EASL	T093	C1708333
28420030	222	229	primary	T080	C0205225
28420030	230	240	diagnostic	T060	C0430022
28420030	241	249	modality	T078	C0695347
28420030	254	257	PSC	T047	C0566602
28420030	259	293	magnetic resonance cholangiography	T060	C1697842
28420030	295	298	MRC	T060	C1697842
28420030	325	371	endoscopic retrograde cholangiopancreatography	T060	C0008310
28420030	373	377	ERCP	T060	C0008310
28420030	380	388	Moderate	T080	C0205081
28420030	389	396	quality	T080	C0332306
28420030	397	405	evidence	T078	C3887511
28420030	407	413	strong	T080	C0442821
28420030	414	428	recommendation	T170	C1545264
28420030	432	436	ESGE	T093	C1708333
28420030	439	443	EASL	T093	C1708333
28420030	457	461	ERCP	T060	C0008310
28420030	483	486	MRC	T060	C1697842
28420030	492	504	liver biopsy	T060	C0193388
28420030	508	517	equivocal	T080	C0332241
28420030	521	536	contraindicated	T033	C0420587
28420030	540	548	patients	T101	C0030705
28420030	574	583	suspicion	T033	C0243095
28420030	587	590	PSC	T047	C0566602
28420030	596	601	risks	T078	C0035647
28420030	605	609	ERCP	T060	C0008310
28420030	641	650	potential	T080	C3245505
28420030	651	658	benefit	T081	C0814225
28420030	674	686	surveillance	T058	C0700325
28420030	691	700	treatment	T061	C0087111
28420030	701	716	recommendations	T170	C1545264
28420030	718	721	Low	T080	C0205251
28420030	722	729	quality	T080	C0332306
28420030	730	738	evidence	T078	C3887511
28420030	740	744	weak	T080	C1762617
28420030	745	759	recommendation	T170	C1545264
28420030	763	767	ESGE	T093	C1708333
28420030	770	774	EASL	T093	C1708333
28420030	792	800	patients	T101	C0030705
28420030	809	830	established diagnosis	T080	C0332139
28420030	834	837	PSC	T047	C0566602
28420030	839	842	MRC	T060	C1697842
28420030	871	882	therapeutic	T061	C0087111
28420030	883	887	ERCP	T060	C0008310
28420030	889	893	Weak	T080	C1762617
28420030	894	908	recommendation	T170	C1545264
28420030	910	913	low	T080	C0205251
28420030	914	921	quality	T080	C0332306
28420030	922	930	evidence	T078	C3887511
28420030	934	938	ESGE	T093	C1708333
28420030	941	945	EASL	T093	C1708333
28420030	965	975	endoscopic	T060	C0014245
28420030	976	985	treatment	T061	C0087111
28420030	991	1002	concomitant	T079	C0521115
28420030	1003	1009	ductal	T023	C0005400
28420030	1010	1018	sampling	T078	C0870078
28420030	1020	1034	brush cytology	T074	C0490961
28420030	1036	1056	endobiliary biopsies	T074	C1737508
28420030	1061	1070	suspected	T080	C0332147
28420030	1071	1082	significant	T078	C0750502
28420030	1083	1093	strictures	T190	C0597984
28420030	1108	1111	MRC	T060	C1697842
28420030	1115	1118	PSC	T047	C0566602
28420030	1119	1127	patients	T101	C0030705
28420030	1145	1153	symptoms	T184	C1457887
28420030	1164	1171	improve	T033	C0184511
28420030	1182	1192	endoscopic	T060	C0014245
28420030	1193	1202	treatment	T061	C0087111
28420030	1204	1210	Strong	T080	C0442821
28420030	1211	1225	recommendation	T170	C1545264
28420030	1227	1230	low	T080	C0205251
28420030	1231	1238	quality	T080	C0332306
28420030	1239	1247	evidence	T078	C3887511
28420030	1251	1255	ESGE	T093	C1708333
28420030	1258	1262	EASL	T093	C1708333
28420030	1263	1272	recommend	T170	C1545264
28420030	1286	1297	anticipated	T033	C3840775
28420030	1298	1306	benefits	T081	C0814225
28420030	1310	1329	biliary papillotomy	T061	C0085263
28420030	1332	1346	sphincterotomy	T061	C0948386
28420030	1359	1364	risks	T078	C0035647
28420030	1390	1396	Strong	T080	C0442821
28420030	1397	1411	recommendation	T170	C1545264
28420030	1413	1421	moderate	T080	C0205081
28420030	1422	1429	quality	T080	C0332306
28420030	1430	1438	evidence	T078	C3887511
28420030	1440	1459	Biliary papillotomy	T061	C0085263
28420030	1462	1476	sphincterotomy	T061	C0948386
28420030	1515	1524	difficult	T080	C0332218
28420030	1525	1536	cannulation	T061	C0917707
28420030	1538	1544	Strong	T080	C0442821
28420030	1545	1559	recommendation	T170	C1545264
28420030	1561	1564	low	T080	C0205251
28420030	1565	1572	quality	T080	C0332306
28420030	1573	1581	evidence	T078	C3887511
28420030	1586	1590	ESGE	T093	C1708333
28420030	1593	1597	EASL	T093	C1708333
28420030	1606	1628	routine administration	T061	C0204888
28420030	1632	1656	prophylactic antibiotics	T061	C0508354
28420030	1657	1663	before	T079	C0332152
28420030	1664	1668	ERCP	T060	C0008310
28420030	1672	1680	patients	T101	C0030705
28420030	1686	1689	PSC	T047	C0566602
28420030	1691	1697	Strong	T080	C0442821
28420030	1698	1712	recommendation	T170	C1545264
28420030	1714	1717	low	T080	C0205251
28420030	1718	1725	quality	T080	C0332306
28420030	1726	1734	evidence	T078	C3887511
28420030	1739	1743	EASL	T093	C1708333
28420030	1746	1750	ESGE	T093	C1708333
28420030	1751	1760	recommend	T170	C1545264
28420030	1766	1784	cholangiocarcinoma	T191	C0206698
28420030	1786	1789	CCA	T191	C0206698
28420030	1801	1810	suspected	T047	C0277540
28420030	1818	1825	patient	T101	C0030705
28420030	1831	1840	worsening	T033	C1820858
28420030	1841	1852	cholestasis	T047	C0008370
28420030	1854	1865	weight loss	T046	C2911645
28420030	1867	1873	raised	T080	C0442818
28420030	1874	1879	serum	T031	C0229671
28420030	1880	1886	CA19-9	T059	C0201551
28420030	1895	1898	new	T080	C0205314
28420030	1902	1913	progressive	T169	C0205329
28420030	1914	1922	dominant	T169	C1527180
28420030	1923	1932	stricture	T190	C0597984
28420030	1966	1975	enhancing	T052	C2349975
28420030	1976	1987	mass lesion	T191	C0746408
28420030	1989	1995	Strong	T080	C0442821
28420030	1996	2010	recommendation	T170	C1545264
28420030	2012	2020	moderate	T080	C0205081
28420030	2021	2028	quality	T080	C0332306
28420030	2029	2037	evidence	T078	C3887511
28420030	2042	2046	ESGE	T093	C1708333
28420030	2049	2053	EASL	T093	C1708333
28420030	2054	2063	recommend	T170	C1545264
28420030	2064	2070	ductal	T023	C0005400
28420030	2071	2079	sampling	T078	C0870078
28420030	2081	2095	brush cytology	T074	C0490961
28420030	2097	2117	endobiliary biopsies	T074	C1737508
28420030	2134	2141	initial	T079	C0205265
28420030	2142	2155	investigation	T058	C0220825
28420030	2164	2173	diagnosis	T033	C0011900
28420030	2178	2185	staging	T060	C0027646
28420030	2189	2198	suspected	T047	C0277540
28420030	2199	2202	CCA	T191	C0206698
28420030	2206	2214	patients	T101	C0030705
28420030	2220	2223	PSC	T047	C0566602
28420030	2225	2231	Strong	T080	C0442821
28420030	2232	2246	recommendation	T170	C1545264
28420030	2248	2252	high	T080	C0205250
28420030	2253	2260	quality	T080	C0332306
28420030	2261	2269	evidence	T078	C3887511